Results & Expectations
    Retatrutide

    Retatrutide Before and After: 71 Pounds

    Seventy-one pounds. That is roughly what a participant at the highest retatrutide dose lost on average in Phase 2 -- a transformation that changed not just a number on the scale, but an entire health trajectory.

    Published: April 3, 202613 min read

    Numbers in clinical trials can feel abstract. "24% body weight loss" is a statistic. But 71 pounds is a person who no longer avoids mirrors. It is a closet of clothes that no longer fits -- because they are all too big. It is a set of stairs that no longer requires rest halfway up. It is a blood sugar reading that no longer says "diabetic." Phase 2 of the retatrutide trial (Jastreboff et al., NEJM 2023) produced these transformations routinely at the highest dose, and Phase 3 will determine whether they hold up across thousands of patients.

    Data Context

    The 71-pound figure is approximate, based on 24% average weight loss at the highest dose for a participant starting around 296 pounds. Individual results vary significantly. Clinical trials do not publish individual before/after photos. Retatrutide is investigational.

    The Timeline of Transformation

    Seventy-one pounds did not disappear overnight. It accumulated over 48 weeks of consistent treatment. Months 1-2: the first 10-15 pounds, mostly noticed by the patient as looser clothing and a lighter feeling. Months 3-4: 25-35 cumulative pounds lost, noticeable to friends and family. Months 5-8: 45-60 cumulative pounds, dramatic visual transformation requiring new wardrobe. Months 9-12: approaching 71 pounds, the person in the mirror is substantially different from the person who started.

    Health Transformation Beyond Appearance

    The metabolic transformation that accompanies 71 pounds of weight loss is arguably more important than the visual change. Type 2 diabetes markers improve dramatically -- many patients achieve near-normal HbA1c levels, some potentially reaching remission criteria. Blood pressure often normalizes without medication. Liver fat drops by 80%+ thanks to glucagon-driven hepatic fat oxidation. Sleep apnea resolves or dramatically improves. Joint pain decreases as mechanical load drops. Inflammatory markers normalize. The cardiovascular risk profile shifts from high-risk to substantially lower risk.

    What 71 Pounds Looks Like in Daily Life

    • Climbing stairs without breathlessness
    • Fitting into airplane seats comfortably
    • Playing with children or grandchildren without limitation
    • Reduced or eliminated daily medications
    • Improved confidence and social engagement
    • Better sleep quality and more energy throughout the day
    • Ability to exercise that was not possible before

    Setting Your Own "Before and After"

    Your transformation may be 71 pounds, or 40, or 90. The exact number matters less than the direction. Every pound of fat lost improves metabolic health, reduces disease risk, and enhances quality of life. The goal is not perfection -- it is meaningful, sustained improvement that changes your health trajectory.

    To start your own transformation, visit our treatments page.

    Medical Disclaimer

    This article is for educational purposes only. Retatrutide is not FDA-approved. The 71-pound figure is an estimate from Phase 2 data (Jastreboff et al., NEJM 2023). Individual results vary. No individual patient photos from clinical trials are included or endorsed. Consult a healthcare provider.

    Write Your Own Transformation Story

    Start today. Semaglutide from $99/mo, tirzepatide from $125/mo.

    Get Started Today

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    What does the published clinical evidence show for retatrutide?

    Peer-reviewed evidence: Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. (Source: Jastreboff et al. Phase 2 trial, NEJM 2023). Trimi is preparing for launch; compounded availability depends on FDA-cleared compounding pathways. Results vary by individual; eligibility is determined by a licensed clinician.

    Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. — Jastreboff et al. Phase 2 trial, NEJM 2023
    Retatrutide 12 mg reduced HbA1c by approximately 2.02 percentage points at 36 weeks in patients with type 2 diabetes, compared with 1.41 points on dulaglutide 1.5 mg. — Rosenstock et al. Phase 2 T2D trial, Lancet 2023

    Key Takeaways

    • Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. (Source: Jastreboff et al. Phase 2 trial, NEJM 2023)
    • Retatrutide 12 mg reduced HbA1c by approximately 2.02 percentage points at 36 weeks in patients with type 2 diabetes, compared with 1.41 points on dulaglutide 1.5 mg. (Source: Rosenstock et al. Phase 2 T2D trial, Lancet 2023)
    • Retatrutide is investigational and not FDA-approved as of publication. Trial findings reported here are from Phase 2 / Phase 3 studies in peer-reviewed sources cited below.
    • Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
    • This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: April 3, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    Arrived within 24 hours. Easy to use. Comes with everything. The year is so worth it.

    Outcome: Same-day delivery experience

    Veronica LarimoreFacebook
    It's only been 2 weeks since I've been taking the VialsRx meds from Trimi. The medication showed up pretty quickly (about 4 days after getting approval from Trimi prescriber) and I received 3 vials for my first 3 months on the subscription. For the price and convenience my take is that Trimi and VialsRx is good.

    Outcome: 4-day delivery; 3 vials for first 3 months; price + convenience verdict positive

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2301972
    2. Rosenstock J, Frias J, Jastreboff AM, et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. The Lancet.Read StudyDOI: 10.1016/S0140-6736(23)01053-X
    3. ClinicalTrials.gov (2024). A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Are Overweight (TRIUMPH-1) — NCT05929066. ClinicalTrials.gov.Read Study
    4. Garvey WT, Mechanick JI, Brett EM, et al. (2024). American Association of Clinical Endocrinology / American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice.Read StudyDOI: 10.4158/EP161365.GL
    5. American Heart Association (2021). Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation.Read StudyDOI: 10.1161/CIR.0000000000000973
    6. Apovian CM, Aronne LJ, Bessesen DH, et al. (2015). Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism.Read StudyDOI: 10.1210/jc.2014-3415

    Was this article helpful?

    Keep Reading

    What losing 71 pounds on retatrutide looks like: the transformation from Phase 2 trial data, health improvements, timeline, and what patients can realistically expect from the triple agonist.

    Get answers to the 30 most common questions about retatrutide, from how it works and side effects to cost, availability, eligibility, and results based on Phase 2 clinical trial data.

    The definitive 2026 guide to retatrutide (LY3437943): mechanism of action, Phase 2 and 3 trial results, dosing, side effects, cost, availability, eligibility, and how to get started.

    Retatrutide 1mg is the micro-starting dose used to introduce the body to triple receptor activation. Expected effects, side effects, why starting low matters, and what to expect before titrating up.

    Start your GLP-1 journey — from $99/mo

    Get Started